OBJECTIVES: The aim of this study was to examine the impact of etanercept (ETN) therapy on work productivity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and psoriasis (PS), who are not responding to disease-modifying antirheumatic drugs (DMARDs) in prospective real world observation in the Czech Republic. The data collection is still ongoing. METHODS: Work productivity was examined in 17 working patients (6-RA, 8-PsA and 6-PS) using the Health and Work Productivity Questionnaire (HPQ) before ETN treatment initiation and after 3 months of treatment. Productivity losses were monetized using average wage calculated by friction cost (FC) and human capital (HC) approaches. We also measured health-related quality of life (HRQoL) using the EQ-5D-3L questionnaire. RESULTS: The baseline values of absenteeism (Ab), presenteeism (Pr) and total HPQ score were 0.062, 0.754 and 0.693, respectively. Ab decreased to 0.000 while Pr and total HPQ score significantly increased to 0.899 (p = 0.0456 and 0.006) after 3 months of treatment. The average productivity loss per patient was €1,705 (FC) or €38,819 (HC) at the baseline and it decreased to €573 (FC) or €12,971 (HC) after the three months of ETN therapy. The largest change in total HPQ score was 0.211 in RA (PsA-0.197, PS-0.166). Consequent changes in productivity losses were equal to -€1,175 (FC) or -€25,495 (HC) in RA, -€1,062 (FC) or -€16,536 (HC) in PsA, and -€921 or -€35,743 (HC) in PS. The 3-months ETN therapy also significantly increased the HRQoL: the baseline EQ-5D-3L index of 0.659 increased to 0.880 (p<0.001) and EQ-VAS score of 39.5 increased to 70.9 (p<0.001). CONCLUSIONS: Modern biological anti-TNF (etanercept) therapy has proved to substantially decrease the negative effect of RA, PsA and PS on patients’ work productivity leading to lower productivity costs and also improvement of theirs quality of life.